Despite the Obama administration's stepped-up regulatory attack on tax inversions, experts say the rules likely won't block the $160 billion deal announced Monday by U.S. pharmaceutical giant Pfizer and Ireland-based rival Allergan.
Larry Harding, International tax expert at Radius, discusses how Pfizer and Allergan are to combine in the largest healthcare deal in history.
Pfizer Inc. and Allergan on Monday announced a $160-billion merger that would create the world’s largest drugmaker while increasing pressure on Washington policymakers to address corporate tax policy because the deal would shelter the new firm's global earnings.
Izzy Jacques is a senior associate at Radius, a Boston firm that helps companies that are expanding internationally with different kinds of business needs. She was on the lookout for tech companies that Radius could partner with.
With Global HR, companies can reduce risk and save time by managing all of their international employees through a combination of international HR advisory expertise and cloud-based software.